What a PROCEED verdict actually contains: a breakdown of GCI's 10 report sections

The three possible verdicts

Inside a PROCEED report: the 10 sections

Section 1: Macro and market context

We evaluate the macroeconomic environment that will shape this investment over the next 24 to 36 months. Analysis includes GDP growth trends, interest rate outlook, foreign investment flows, currency stability, and sector-specific demand drivers. For a real estate play in Dubai, we assess mortgage rate environment, visa policies, and GCC expat inflows. Output is a clear statement of tailwinds and headwinds the deal will face. No opportunity exists in a vacuum.

Section 2: Sector dynamics and growth signals

We examine whether the sector is expanding, stabilizing, or contracting. Analysis looks at historical compound growth rates, market size estimates, player consolidation, and regulatory trends affecting the sector. For a clinic acquisition, we evaluate healthcare spending growth in the emirate, patient demographics, and whether the market is oversupplied or undersupplied. We identify whether the opportunity is riding a growth wave or swimming against current headwinds.

Section 3: Regulatory and licensing environment

We assess whether the regulatory pathway is clear or blocked. For a clinic acquisition, Section 3 evaluates DHA licensing requirements, advertising compliance, staff transfer protocols, and any pending regulatory changes. For a fintech play, we analyze whether the activity is licensed, sandboxed, or prohibited. Output includes a timeline for approvals, probability of conditions, and required stakeholder submissions. Regulatory surprises are the costliest kind.

Section 4: Location and site analysis

For real estate-dependent opportunities, we evaluate site quality: accessibility, competitive proximity, demographic fit, lease terms, and landlord stability. For a retail investment, analysis includes foot traffic data, co-tenant quality, lease escalations, and landlord financials. For service businesses, we assess catchment population, travel time, signage visibility, and renewal risk. Location arbitrage or disadvantage can easily erase projected margins.

Section 5: Financial modelling (upside, base, downside)

We build three scenarios: base case with realistic assumptions, upside case with favorable conditions, and downside case with revenue pressure or cost inflation. We evaluate revenue projections against historical comparables, EBITDA margins against sector benchmarks, and debt service coverage against lender requirements. We identify which assumptions drive value and which are defensible. Output is a clear sensitivity analysis: if rent increases 10% or occupancy drops 15%, what happens to returns?

Section 6: Corporate tax and VAT position

We evaluate the tax structure of the vehicle, VAT registration implications, withholding obligations, and any changes to the tax code that will affect profitability. For acquisitions, we assess whether deductions for depreciation, interest, or losses are available. For distributions, we review dividend withholding, partnership tax treatment, and transfer pricing compliance. Output is a quantified tax drag expressed as a percentage of projected returns.

Section 7: Competitive landscape

We identify the direct and indirect competitors for this investment. Analysis includes competitor count, market share distribution, pricing power, brand strength, and ability to differentiate. For a clinic, we map all licensed clinics within 2km, their patient capacity, staff turnover, and patient reviews. For a retail brand, we assess comparable store productivity and competitive pricing. We identify whether the opportunity gains competitive advantage or faces price pressure.

Section 8: Risk matrix with probability ratings

We identify 8 to 12 material risks specific to the deal: regulatory changes, competitor response, cost inflation, key person dependence, supply chain disruption, or customer concentration. For each risk, we estimate probability and financial impact. A 30% probability of a 40% revenue decline is material and will affect whether we proceed. Output is a ranked list of risks, not a generic checklist.

Section 9: Required diligence actions

We specify what you should investigate with lawyers, accountants, and advisors. Example: confirm that the clinic's medical director will remain post-acquisition, obtain regulatory approval letter for staff transfers, reconcile historical patient volumes to projected growth. We distinguish between low-priority confirmations and deal-breaker conditions. This section saves your advisors time by pointing them to the right questions.

Section 10: Final verdict with entry structure recommendation

We deliver one of three verdicts with specific reasoning. We recommend deal structure: direct equity, partnership, franchise, or partnership. We identify the maximum price you should pay given your cost of capital and the risk profile. We state the IRR breakeven assumption that must hold. This is where conviction becomes actionable decision.